Introducing Origen™ by Cellino. Preserve your healthiest cells today. Join waitlist →

Your Cells Are
Your Future

We reset your cells to a youthful biological state and securely store them for future regenerative therapies. Your biology, preserved at its healthiest starting point.

Join waitlist

"We live 80-year lives in bodies built for 40. For the first time, we can do something about it."

- Nabiha Saklayen, PhD, Co-Founder & CEO

"This is the frontier of drug development that is poised to change the industry."

Forbes

"Cellino will help enable a host of diseases to be cured through stem cell therapy."

WSJ

"Cellino's angle is also very unique with an automated system that could make cells for every human being."

TechCrunch

Origen™

iPSCInduced pluripotent stem cells - your own cells reprogrammed to act like blank slates, able to become nearly any cell type in your body. Starting Reserve by Cellino

Your personalized cell preservation service. Origen collects a simple blood sample, validates your cells through rigorous quality testing, and cryopreserves them in state-of-the-art facilities, building your foundational cell bank for whatever the future of medicine brings.

Join waitlist
Simple
Blood Draw
Secure
Storage
You Own
Your Cells

What You Get

  • Minimally invasive sample collection (15-minute blood draw)
  • Rigorous PBMCPeripheral blood mononuclear cells - immune cells from your blood that serve as the starting material for creating your own iPSCs (induced pluripotent stem cells), which can become virtually any cell type in your body. quality testing & validation
  • Long-term cryopreservation in state-of-the-art facilities
  • Access to your cells when future therapies become available
  • Founding Circle membership: dedicated support for cell status updates, therapy access, and priority onboarding as treatments go live
$120M+
Backed by Khosla, 8VC, Felicis, Bayer, and ARPA-H
FDA
Advanced Manufacturing Technology designation
10+
Patents protecting our approach
14+
Years of global Nobel Prize-winning research in regenerative medicine
115+
Clinical trials globally exploring PSCs for therapeutic use

How It Works

A simple blood draw. 15 minutes. From there, Cellino handles everything.

Simple Blood Draw

A quick 15-minute blood draw. That's all we need. One sample to start the entire process.

~15 minutes

Select, Convert & Validate

Cellino captures your whole blood, selects and converts cells to PBMCs, then runs quality checks for viability, purity, and sterility.

Cellino handles this

Cryopreserved & Banked

Your validated cells are cryopreserved and stored in independent, state-of-the-art biobanking facilities, ready for research use and therapies as they arrive.

Stored for the future
Join waitlist

See how it works from our CEO

Dr. Nabiha Saklayen, Harvard-trained PhD physicist and Cellino CEO, walks you through the process from blood draw to banked cells.

Join waitlist
The Regenerative Collective

Join the
Regenerative
Collective

A circle for those investing in their biological future. Reserve your place before we open to the public.

JOIN NOW
Member Benefits
Exclusive collective pricing
Priority access to future Origen products and services
Quarterly insider updates from CEO Nabiha Saklayen
First look at research milestones before public release
Invite-only AMAs with Cellino's founders and science team
Early access to Origen's beta tester group
Private Regenerative Collective member community
Partner discounts across wellness, longevity, and diagnostics
ACTIVE PROGRAMS

Our manufacturing platform is actively supporting manufacturing scale up across multiple indications.

Parkinson's Disease

Mass General Brigham Gene and Cell Therapy Institute

Phase 1 clinical trial for a novel autologous iPSC-derived Parkinson's therapy, led by neurosurgeon Dr. Jeffrey Schweitzer.

Our collaboration

Cellino is building the world's first hospital-based autologous iPSC Foundry at Mass General Brigham's Gene and Cell Therapy Institute (GCTI), powered by our Nebula™ platform. We're manufacturing patient-specific iPSCs for the trial, bringing automated production directly into the clinical setting.

Press Release

Cardiovascular Disease

Karis Bio

iPSC-derived endothelial cell therapy designed to regenerate blood vessels in patients with peripheral artery disease and coronary artery disease. First-in-human study underway in South Korea.

Our collaboration

Cellino is industrializing autologous iPSC manufacturing for Karis Bio's cardiovascular programs using our Nebula™ platform. This partnership marks Cellino's first expansion into the Asia-Pacific region.

Press Release

Spinal Cord Injury

Matricelf

Fully autologous engineered neural tissue for spinal cord injury repair, combining patient-derived iPSCs with a hydrogel scaffold from the patient's own tissue. IND filing expected 2026.

Our collaboration

Cellino manufactured and delivered autologous iPSC lines from multiple donors. Matricelf successfully differentiated these into functional neural tissues showing synchronized electrical activity - with results comparable to their own internally produced iPSCs.

Press Release
WHY PRESERVE YOUR CELLS

Your cells unlock two things, not one

Both start from the same blood draw. Both get more valuable over time.

Research Use

Your cellular twin

A crash test dummy for your health, made from your actual cells. Not frozen storage. A living model of you: actively differentiated for drug screening, disease modeling, and biological aging comparison.

Drug screening · Disease modeling · Personalized insights · Longevity research
Clinical Path

Cell & tissue replacement

As iPSC-derived therapies gain approval, your banked PBMCs become the starting material. Retinal cells for vision. Neurons for Parkinson's. Cartilage for joints. Made from you, for you. No starting from scratch at 60 with 60-year-old cells.

Autologous therapies · Tissue engineering · Clinical trial readiness
The Case for Now

Why Bank Now?

Your cells are the youngest they'll ever be. The sooner you bank, the higher quality your starting material - and the better your future therapies can be. No age is too old to start, but every year you wait means more accumulated mutations in your cells.

Today Is Your Youngest Day

Every day that passes, your cells accumulate more DNA mutations. Banking now captures them at their lowest mutation burden - the best possible starting material for future therapies. The younger your cells, the higher quality the end product.

Be First in Line

iPSC-derived therapies are entering clinical trials now. By banking today, your cells will already be preserved, validated, and ready to go when these therapies become available. Don't wait until you need them to start the process.

It's Never Too Late

Whether you're 25 or 65, your cells still hold immense potential. While younger cells provide the highest quality starting material, banking at any age gives you options you wouldn't otherwise have. The best time to start is now.

Your Future Self Will Thank You

This isn't about fear - it's about agency. When regenerative therapies arrive for your condition, you'll already have the starting material locked in at its best. No scrambling with older, degraded cells when you need them most.

"In 30 years, there is going to be a way to replace the parts of your body that fail you. If you bank your iPSCs now, you will be first in line to access it. In 30 years, would you wish you had your youngest and best starting materials?"

A Different Class of
Cell Banking How iPSC banking compares to today's legacy options

Origen™ by Cellino Egg Freezing / Cord Blood
Available at any age ✓ ✕
Covers your whole body ✓ ✕
Can become any cell type ✓ ✕
Simple blood draw ✓ Varies
Genetically matched to you ✓ ✓
Application possibilities Whole body Limited scope
Grows in value as new therapies launch ✓ ✕
Reserve Your Spot
SCIENTIFIC FOUNDATION

The Science Behind Your Cells

Four breakthrough technologies work together to turn a simple blood draw into your most valuable biological asset.

01

iPSC Science

Your PBMCs are reprogrammed back to a pluripotent state, capable of becoming any cell type in your body. Built on Yamanaka factors, the Nobel Prize-winning breakthrough behind personalized regenerative medicine.

Nobel Prize · 2012
02

Laser-Based Reprogramming

Precise, non-contact laser control at the single-cell level initiates reprogramming without manual handling.

Single-cell precision
03

Image-Guided Bioprocessing

High-resolution imaging monitors every cell's morphology and behavior in real time throughout reprogramming and expansion. Quality decisions are based on what's actually happening, not batch averages.

Real-time quality control
04

AI & Machine Learning

Machine learning models interpret imaging data and drive adaptive process control. Automated decision-making replaces manual judgment to deliver consistent, reproducible outcomes at scale.

Automated at scale

Building for an accessible future for everyone at scale.

Our platform holds FDA Advanced Manufacturing Technology designation, builds on the 2012 Nobel Prize in Physiology or Medicine, and is actively supporting manufacturing scale up at Mass General Brigham, Karis Bio, and Matricelf.

Nobel Prize Science

In 2012, Shinya Yamanaka shared the Nobel Prize for discovering that adult cells can be reprogrammed into pluripotent stem cells. Your cells can become any cell type: heart, brain, retina, cartilage, blood, skin.

Laser Reprogramming

Cellino's proprietary laser-based platform enables precise, non-contact reprogramming at the single-cell level. No manual handling, no destructive intervention. Just precision manufacturing at scale.

FDA Designated

Our platform holds FDA Advanced Manufacturing Technology designation with active partnerships with Mass General Brigham, Karis Bio, and Matricelf. This isn't theoretical. It's happening now.

Multiple Applications

Your cells are cryopreserved in independent, regulated biobanking facilities with redundant systems and continuous monitoring. Not in our offices, but in purpose-built medical infrastructure.

Your Cells, Your Ownership

Your biological material never gets used for anything without your explicit consent. You decide when and how to use your cells. Your cells, your ownership, your future.

The Clock Is Ticking

Your cells age with you. Every single day. Banking them now means you'll have the youngest, healthiest starting material when therapies reach your condition. The alternative is starting from scratch with older cells.

The Founders

Cellino was founded by scientists who met at Harvard, driven by a shared belief: personalized regenerative health should be accessible to everyone.

Nabiha Saklayen and Marinna Madrid in the Cellino lab
Nabiha Saklayen, PhDCo-Founder & CEO
Marinna Madrid, PhDCo-Founder & CTO
NS
Nabiha Saklayen, PhD
Co-Founder & CEO

Harvard-trained physicist who pioneered laser-enabled precision for complex biological processes. Inventor of cellular laser editing techniques and recipient of the first Tory Burch Fellowship at the Innovative Genomics Institute (IGI).

Member, National Academies Forum on Regenerative Medicine Ernst & Young Entrepreneur of the Year 2025 PhD Physics - Harvard Tory Burch Foundation Fellow
MM
Marinna Madrid, PhD
Co-Founder & CPRO

Applied physicist who co-invented laser-based intracellular delivery techniques at Harvard. Leads Cellino's regulatory strategy, including the FDA-granted Advanced Manufacturing Technology designation. Authored the first review paper on autologous iPSC-based cell therapies.

Forbes 30 Under 30 - Healthcare FDA Advanced Mfg. Designation PhD Applied Physics - Harvard Harvard Graduate Prize Fellow HMS Catalyst Accelerator Grant Multiple Patents & Publications

What You Might Be Wondering

How does the process work? +
It starts with a standard blood draw. 15 minutes, no surgery, nothing dramatic. We purify your immune cells and cryopreserve them at our storage facility. If you choose a higher tier, we go a step further and reprogram those cells into iPSCs on our manufacturing platform, so they're banked and ready for research use now and clinical therapies as they become available. Either way, your starting material is locked in.
When can I actually get a therapy? +
That's the right question to ask. iPSC-derived therapies are in clinical trials right now, across multiple conditions. We can't promise a specific year for broad availability because that depends on trial outcomes and regulatory approval, but the field is moving faster than most people realize. The point of banking now is that when a therapy does reach your condition, you're not starting from zero.
What does it cost? +
We'll share full pricing during the reservation process. We're building this to be accessible to early adopters, not just the ultra-wealthy.
What exactly is an iPSC? +
Think of it as resetting your cells to factory settings. We take your adult immune cells and reprogram them back to an embryonic-like state, which means they can become virtually any cell type: heart, brain, retina, cartilage, blood, skin. They're genetically matched to you, so there's no donor rejection risk. The science behind this won a Nobel Prize in 2012, and clinical trials using iPSCs are running globally.
How is this different from egg freezing or cord blood? +
Egg freezing preserves fertility. Cord blood is collected at birth and limited to certain blood disorders. Both are valuable, but neither covers the rest of your body for the rest of your life. Origen starts from a simple blood draw, with the future option to generate iPSCs that can become any tissue type. It's a fundamentally different category.
Where's the proof this works? +
Japan treated the first patient with iPSC-derived cells in 2014. Since then, trials have launched globally for Parkinson's, osteoarthritis, macular degeneration, heart failure, spinal cord injury, and cancer. Our platform has FDA Advanced Manufacturing Technology designation, and we have active collaborations with Mass General Brigham, Karis Bio, and Matricelf.
Will my doctor be involved? +
That's the goal. We're building clinical partnerships so that when iPSC therapies gain regulatory approval, they can be delivered through established healthcare networks, ideally through your existing care team. Insurance coverage will evolve alongside approvals. Banking now just means you'll have the starting material ready whenever that day comes.
What happens to my cells if the company shuts down? +
They're yours. Full stop. Your cells are held with a third-party cryostorage partner, and we have transfer protocols contractually in place to ensure continuity of storage independent of Cellino's operations. No matter what happens on our end, your biology stays in your hands.
Reserve Your Spot

We Are Not Getting Younger

But for the first time, we have a choice. Simple blood draw. Clinical-grade storage. This is the one decision you can't make later.

Built for the future of regenerative medicine.

Join waitlist

Founding cohort · By invitation

The information on this page is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Cellino does not claim that iPSC banking will treat, cure, or prevent any disease. iPSC-derived therapies are investigational and subject to clinical trial outcomes and regulatory approval. Individual results may vary. The expert quotes presented reflect publicly available statements and do not constitute endorsements of Cellino or its products. Cellino is not a healthcare provider. Always consult a qualified healthcare professional before making decisions about your health. Past scientific achievements and ongoing clinical trials do not guarantee future therapeutic availability or outcomes.

Save Your Cells - Cellino